More tools:Markets·Screener·Research·Chat

Regentis Biomaterials Ltd. (RGNT) Financial Statements

Regentis Biomaterials Ltd.
SIC 8050 · SERVICES-NURSING & PERSONAL CARE FACILITIES
FIGI AK-6870D9674C
XASE · usd
2.03▼ 0.01 (-0.35%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)—
EBITDA—
Diluted EPS (TTM)—
EBITDA Margin—
Net Debt—
Trading Information
Previous Close2.04
Day's Range1.92 – 2.04
52-Week Range1.23 – 15.50
Volume55.8K
Avg Volume55.1K
Share Statistics
Shares Outstanding
Employees8
ExchangeXASE
Listed2025-12-04
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Regentis Biomaterials Ltd. (RGNT)
What is Regentis Biomaterials Ltd.'s Market Cap?
Regentis Biomaterials Ltd.'s Market Cap is $10.5M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023
Research and development expenses, net:
Horizon 2020 grant—
Research and development expenses
Research and development expenses, net
General and administrative expenses
Operating profit (loss)
Financial income (expense), net:
Change in fair value of convertible notes
Changes in fair value of warrant liability
Other financing expense, net
Financial income (expense), net
Net income (loss) and comprehensive income (loss)
Basic net income (loss) per share
Dilutednet income (loss) per share